Automation
Architecture review before implementation
Implementation scope and rollout planning
Clear next-step recommendation
A custom workflow that automates the fusion of radiological phenotypes with genomic biomarkers to accelerate biomarker discovery and personalized treatment planning.
This workflow automates the high-labor, error-prone process of manually correlating imaging findings with genomic test results. It eliminates weeks of data wrangling by researchers, directly accelerating the path from raw data to actionable insights for clinical trials and treatment decisions. The operational upside comes from compressing analysis timelines, improving cohort identification accuracy, and enabling scalable, reproducible research across patient populations.
Implementation requires a privacy-by-design architecture, integrating with Epic or Cerner via FHIR, PACS via DICOM, and lab systems like Clarity LIMS. The correlation engine uses retrieval-augmented agents to map imaging phenotypes (e.g., tumor texture, growth patterns) to genomic pathways. Governance is critical: all automated correlations undergo confidence scoring, with low-confidence findings and all potential clinical actions routed to a molecular tumor board for review before any patient impact.
A custom workflow that fuses imaging phenotypes with genomic biomarkers automates the discovery of novel correlations, accelerating personalized treatment planning and research while reducing the manual data synthesis burden from weeks to hours.
Manual correlation of imaging features (e.g., tumor texture, vascularity) with genomic variants (e.g., EGFR, KRAS) is a slow, expert-driven process prone to oversight. A custom automation workflow uses multimodal agents to query genomic databases (e.g., EHR-linked labs, cBioPortal), align findings with segmented imaging phenotypes, and run statistical analyses continuously. This reduces discovery cycles from 3-6 months of manual literature review and cohort analysis to continuous, automated hypothesis generation, allowing research and clinical teams to validate novel imaging biomarkers in weeks instead of quarters.
Clinicians and bioinformaticians spend hours per patient manually retrieving DICOM studies from PACS, extracting genomic reports from the EHR or LIMS, and aligning data in spreadsheets or bespoke scripts. An orchestrated workflow automates this via HL7/FHIR listeners for genomic lab results, DICOM query-retrieve agents for imaging, and a privacy-aware data-lake layer that tokenizes and links records. This eliminates 15-25 hours of manual synthesis per research case, reallocating expert time to validation and clinical decision-making instead of data wrangling.
Identifying patients with specific imaging phenotypes and genomic markers for trial enrollment is a high-friction, low-yield manual screening process. A custom workflow continuously screens incoming imaging and genomic data against trial inclusion criteria using a rules engine and vector similarity search. It generates a prioritized, pre-qualified candidate list with aligned evidence, boosting enrollment rates and reducing the screening labor required from clinical research coordinators by over 60%.
Relying on incomplete data correlations can lead to suboptimal treatment pathways. This workflow embeds automated cross-validation checks between imaging segmentation confidence scores and genomic assay quality flags. Low-confidence correlations are routed for multidisciplinary review (e.g., to a molecular tumor board dashboard), while high-confidence alignments generate auditable evidence briefs. This creates a systematic, defensible linkage between imaging findings and actionable mutations, reducing diagnostic uncertainty and supporting more precise therapy selection.
Moving from pilot projects to institution-wide precision oncology requires repeatable, governed data operations. This workflow architecture provides a production-grade orchestration layer (using tools like LangGraph or Apache Airflow) that integrates with Epic, Cerner, Siemens PACS, and genomic platforms. It includes monitoring for data drift in both imaging AI models and genomic reference databases, ensuring correlations remain valid over time. This turns a research capability into a clinical operating model that can scale across thousands of patients annually.
Beyond operational efficiency, automated correlation creates tangible IP and revenue opportunities. The workflow can be designed to flag novel, high-value phenotype-genotype associations and route them to an IP review committee with supporting evidence packages. For academic medical centers and biopharma partners, this accelerates the path from discovery to patentable biomarkers, companion diagnostic development, or licensing deals, transforming data synthesis from a cost center into a strategic asset.
A custom workflow that orchestrates AI agents to fuse imaging phenotypes with genomic biomarkers from siloed clinical systems, automating the discovery of correlations that inform personalized treatment plans and accelerate research.
This workflow automates the high-labor, error-prone process of manually correlating radiological findings with molecular lab data. By deploying specialized agents to query EHRs (e.g., Epic, Cerner), genomic data lakes, and PACS, it creates unified patient profiles for precision oncology. The operational upside is a 60-70% reduction in data aggregation time per case, allowing clinicians and researchers to scale biomarker validation and support treatment decisions with higher-throughput, evidence-based reasoning.
Implementation requires a privacy-by-design architecture using HL7/FHIR APIs and de-identification gates before data leaves source systems. The orchestrator, built on frameworks like LangGraph, manages state, handles exceptions, and enforces approval workflows. Critical controls include audit logging of all data accesses, uncertainty quantification for correlation strength, and mandatory review gates for low-confidence matches before any clinical action, ensuring safety and regulatory compliance in production.
This blueprint details the specialized agents and integration architecture required to build a custom workflow that fuses imaging phenotypes with genomic data, accelerating biomarker discovery and personalized treatment planning in precision oncology.
This agent orchestrates secure, privacy-aware queries across fragmented genomic data sources (EHRs, lab LIMS, external registries) to retrieve structured biomarker data (e.g., mutation status, MSI, TMB). It normalizes disparate nomenclatures (e.g., HGVS, legacy codes) into a unified schema and handles consent verification and PHI de-identification before data enters the fusion pipeline. Integration with systems like Epic, Cerner, or LabVantage is critical.
This agent triggers and manages a downstream multimodal segmentation workflow (e.g., lesion detection, tumor volumetry, radiomic feature extraction) from the correlated imaging study in PACS. It selects the appropriate model ensemble based on modality and anatomy, executes inference, and returns a structured JSON of quantitative imaging biomarkers (shape, texture, intensity) ready for correlation. It interfaces with on-prem GPU clusters or cloud inference services.
The core fusion logic resides here. This component uses a retrieval-augmented graph-based model to establish statistical and causal links between imaging phenotypes (e.g., tumor heterogeneity on MRI) and genomic markers (e.g., EGFR mutation). It generates hypotheses (e.g., 'Radiomic feature X correlates with immunotherapy resistance in PD-L1 high patients'), cites evidence from integrated knowledge bases (e.g., PubMed, TCGA), and outputs a confidence-scored correlation matrix.
This agent transforms the raw correlation outputs into a clinician-ready narrative. Using an LLM orchestrated via LangChain or a custom framework, it drafts a structured report that summarizes key imaging-genomic correlations, suggests potential therapeutic implications (e.g., eligibility for targeted trials), and highlights discrepancies requiring review. The draft is formatted for direct import into the EHR or tumor board software, with clear citations to source data.
This is the workflow's control plane. It manages approval gates, logging all actions for HIPAA/GDPR and 21 CFR Part 11 compliance. It routes low-confidence correlations or novel findings to a designated molecular tumor board or bioinformatician for review via a dedicated queue (e.g., in ServiceNow or a custom dashboard). It also handles versioning of all data, models, and decisions, creating a complete audit trail for research reproducibility and clinical validation.
The central nervous system built on a framework like LangGraph. This hub defines the state machine, choreographing the handoffs between all specialized agents and external systems (PACS, EHR, genomic DBs). It manages error handling (e.g., failed API calls, missing data), implements retry logic, and ensures data consistency across the pipeline. This is where the custom workflow's reliability, scalability, and observability (via tools like LangSmith) are implemented.
A phased implementation strategy for a custom workflow that fuses imaging phenotypes with genomic data to accelerate precision oncology research while embedding clinical safety controls.
Phase 1 establishes the foundational data pipeline, focusing on privacy-aware integration. An orchestrator, built with LangGraph, ingests de-identified DICOM studies from PACS and structured genomic biomarker results from the EHR or LIMS via FHIR APIs. This initial layer performs essential data validation, logs all data movements for auditability, and routes exceptions (e.g., missing genomic identifiers, poor image quality) to a human-in-the-loop queue for resolution before any correlation logic runs, ensuring data integrity from the outset.
Phases 2 and 3 introduce the analytical core and production controls. Specialized agents extract quantitative imaging phenotypes (e.g., tumor texture, volume growth) which are fused with genomic variants (e.g., EGFR, PD-L1). A correlation engine, governed by predefined statistical thresholds, generates hypotheses and confidence scores. Low-confidence or novel correlations are automatically escalated for biocurator review. The final phase integrates the output into clinical research databases and trial matching systems, with full model performance monitoring and drift detection to maintain diagnostic-grade reliability in a live setting.
Comparison of manual research processes versus a custom automation workflow for precision oncology biomarker discovery.
| Metric | Manual Research Process | Custom Automation Workflow |
|---|---|---|
Study correlation cycle time | 4-6 weeks | 2-3 days |
Data fusion & extraction labor (FTE/month) | 1.5 FTE | 0.2 FTE |
Cases requiring manual data reconciliation | 100% | 12% |
Audit trail for data provenance & compliance | Spreadsheet-based | Automated, immutable logs |
Actionable biomarker hypotheses generated per quarter | 8-10 | 40-60 |
Time to updated treatment plan post-sequencing | 3-4 weeks | 5-7 days |
Implementing a custom workflow to fuse imaging phenotypes with genomic data raises practical questions about data quality, integration, compliance, and rollout. These answers address the key technical and operational concerns for clinical and research leaders.
The workflow architecture includes a dedicated data-quality agent that validates incoming genomic files (e.g., VCF, FASTQ) against schema and completeness rules before processing. For missing or ambiguous data, the system logs the issue to an exception queue and can trigger automated requests back to the LIMS or EHR via HL7/FHIR. Critical missing fields halt the correlation pipeline and route the case for manual review, ensuring no analysis proceeds on incomplete evidence. This gate prevents downstream errors and forces data remediation at the source.
Enabling Efficiency, Speed & Accuracy
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
This workflow automates the fusion of imaging phenotypes with genomic data to accelerate precision oncology, requiring robust governance for clinical safety and continuous validation in production.
This automation directly accelerates biomarker discovery and personalized treatment planning by eliminating the manual, error-prone process of correlating radiology reports with lab results from fragmented EHRs and genomic databases. The operational upside comes from reducing the research cycle for identifying imaging-genomic associations from weeks to hours, enabling faster cohort stratification for clinical trials and more timely therapeutic decisions. Implementation requires a privacy-by-design architecture integrating with Epic or Cerner via FHIR, genomic data lakes, and PACS, using orchestration tools like LangGraph to manage data retrieval, alignment logic, and multimodal reasoning agents.
Governance is enforced through automated checks for patient consent and PHI handling before data retrieval, with all correlation outputs routed through a clinical validation gate staffed by molecular pathologists. The architecture must include detailed audit trails of data provenance, model inferences, and every human override to satisfy regulatory scrutiny for in vitro diagnostics. Continuous validation is achieved by monitoring the clinical utility of generated hypotheses against eventual treatment outcomes, triggering model retraining when correlation performance drifts, ensuring the system remains safe and effective as genomic knowledge evolves.
About the author
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
How We Work
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
The first call is a practical review of your use case and the right next step.
